Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must use their independent medical judgment in all patient care decisions. The information provided is based on current medical knowledge and guidelines but may not encompass all possible scenarios or individual patient variations. Always consult with relevant specialists and consider individual patient factors.

---

Scrub Encephalitis

Overview

• Definition: Scrub encephalitis refers to a severe neurological complication of Scrub Typhus, an acute febrile illness caused by the obligate intracellular bacterium Orientia tsutsugamushi. It manifests as inflammation of the brain parenchyma, often associated with systemic vasculitis, leading to a range of neurological symptoms. While central nervous system (CNS) involvement is common in severe scrub typhus (e.g., altered mental status, headache), overt encephalitis (encephalopathy with focal neurological signs, seizures, or signs of meningeal irritation) is a more serious manifestation.
• Epidemiology: Scrub typhus is endemic in the "tsutsugamushi triangle," a vast geographic area extending from northern Japan and eastern Russia to northern Australia and west to Pakistan and Afghanistan. The highest incidence is in East Asia, Southeast Asia, and the Pacific Islands. Millions of cases occur annually, with up to 1 million deaths globally. Encephalitis as a complication occurs in a significant proportion of severe cases, ranging from 1% to 20% in various series, particularly in patients with delayed diagnosis or treatment. It is more common in adults than children.
• Classification: Scrub encephalitis is primarily classified as a severe neurological manifestation of scrub typhus. It can present as:
  • Diffuse encephalopathy: Altered consciousness without focal signs.
  • Focal encephalitis: Associated with focal neurological deficits.
  • Meningoencephalitis: Combination of meningitis and encephalitis.
  • Other neurological manifestations can include meningitis, cerebellitis, transverse myelitis, cranial nerve palsies, and polyneuropathy, which may coexist with or mimic encephalitis.

Pathophysiology

• Mechanism: Orientia tsutsugamushi is transmitted to humans through the bite of infected larval trombiculid mites (chiggers). The bacterium primarily infects endothelial cells, leading to a widespread vasculitis involving small blood vessels in various organs, including the brain.
  • Endothelial damage: Orientia replicates within endothelial cells, causing cell injury and dysfunction, increased vascular permeability, and perivascular inflammatory infiltrates.
  • Systemic inflammatory response: This vasculitis triggers a robust host inflammatory response, leading to a "cytokine storm" with release of pro-inflammatory mediators (e.g., TNF-α, IL-6), contributing to microvascular leakage, edema, and tissue damage.
  • Cerebral involvement: In the brain, this vasculitis causes cerebral edema, petechial hemorrhages, microinfarcts, and perivascular cuffing by inflammatory cells, leading to neuronal dysfunction and damage. The blood-brain barrier integrity can be compromised.
  • Direct infection vs. immune-mediated: While direct bacterial invasion of CNS cells may occur, the primary mechanism is thought to be inflammatory and immune-mediated vasculitis affecting the cerebral vasculature.
• Risk Factors:
  • Geographic exposure: Travel or residence in endemic areas, particularly rural or forested regions.
  • Occupational exposure: Farmers, forest workers, military personnel, and outdoor enthusiasts.
  • Environmental factors: Exposure to mite-infested vegetation (e.g., tall grasses, scrub brush).
  • Delayed diagnosis/treatment: Prolonged untreated infection increases the risk of severe complications.
  • Host factors: Immunocompromised status (less clear evidence), genetic predispositions may play a role in severity.
• Protective Factors:
  • Avoiding mite bites: Wearing protective clothing (long sleeves, pants), using insect repellents containing DEET or permethrin, avoiding highly vegetated areas.
  • Prompt diagnosis and treatment: Early initiation of appropriate antibiotics significantly reduces the risk of severe complications, including encephalitis.
  • Vector control: Clearing vegetation around homes and campsites, although challenging on a large scale.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Encephalitis typically presents within 1-3 weeks of exposure, often following a prodromal febrile illness.
  • Fever: High-grade fever (often >39°C or 102.2°F) is universally present.
  • Headache: Severe, persistent headache.
  • Altered mental status: Ranging from lethargy, confusion, disorientation, to stupor and coma. This is the hallmark of encephalitis.
  • Eschar: A pathognomonic necrotic lesion at the mite bite site, often painless, with a black scab surrounded by an erythematous halo. Present in ~50-80% of cases (variable by region and patient skin tone).
  • Rash: Maculopapular rash, typically appearing on the trunk and spreading to the extremities, often non-pruritic, present in ~30-50%.
• Early Signs:
  • Non-specific flu-like symptoms: Fever, chills, myalgia, arthralgia.
  • Headache, malaise.
  • Eschar may develop early, but often goes unnoticed.
• Advanced Signs:
  • Seizures: Focal or generalized, reflecting cortical irritation.
  • Focal neurological deficits: Hemiparesis, cranial nerve palsies (e.g., facial palsy, ocular palsies), ataxia, dysarthria, reflecting specific brain region involvement.
  • Signs of increased intracranial pressure (ICP): Papilledema (rare), vomiting, severe headache.
  • Meningismus: Nuchal rigidity, Kernig's and Brudzinski's signs (suggesting meningoencephalitis).
  • Psychiatric symptoms: Hallucinations, psychosis, agitation.
  • Severe systemic manifestations: Acute respiratory distress syndrome (ARDS), myocarditis, renal failure, gastrointestinal bleeding, disseminated intravascular coagulation (DIC).
• Atypical Presentations:
  • Absence of eschar or rash can make diagnosis challenging.
  • Isolated neurological symptoms without prominent systemic signs.
  • Presentations mimicking stroke, Guillain-Barré syndrome, or other infectious encephalitides.

Physical Examination

• Inspection:
  • General: Ill appearance, signs of dehydration, altered level of consciousness.
  • Skin: Presence of an eschar (typically 0.5-2 cm, painless ulcer with black crust) – critically important to search for in intertriginous areas, axillae, groin, perineum, beneath breasts. Maculopapular rash.
  • Eyes: Nystagmus, pupillary abnormalities, gaze palsies. Papilledema (rare).
  • Neck: Nuchal rigidity.
• Palpation:
  • Lymphadenopathy: Regional lymphadenopathy near the eschar, or generalized lymphadenopathy.
  • Abdomen: Hepatomegaly or splenomegaly may be present.
• Special Tests:
  • Neurological examination: Detailed assessment of mental status (Glasgow Coma Scale or similar), cranial nerves, motor and sensory function, reflexes, coordination, and gait. Look for focal deficits, seizures, signs of meningeal irritation (Kernig's, Brudzinski's).

Diagnostic Approach

History Taking

• Key Questions:
  • Geographic exposure: Recent travel to or residence in endemic areas (e.g., Southeast Asia, Pacific Rim)?
  • Environmental exposure: Activities in rural areas, forests, fields, or scrubland? Exposure to tall grasses or brush?
  • Duration of symptoms: Onset of fever, headache, altered mental status?
  • Associated symptoms: Rash, eschar (ask about any painless sores), myalgia, cough, gastrointestinal symptoms.
  • Comorbidities: Immunocompromised status, chronic diseases.
  • Medication history: Prior antibiotic use.
• Red Flags:
  • Rapid progression of altered mental status.
  • New-onset seizures.
  • Development of focal neurological deficits.
  • Signs of increased intracranial pressure (e.g., persistent vomiting, severe headache).
  • Evidence of multi-organ dysfunction (e.g., respiratory distress, oliguria, hypotension).
  • Travel history to endemic regions with unexplained fever and neurological symptoms.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC): Leukopenia or normal leukocyte count with atypical lymphocytes, thrombocytopenia (common in severe cases).
  • Liver Function Tests (LFTs): Elevated transaminases (AST/ALT) are common.
  • Renal Function Tests (RFTs): Elevated creatinine, blood urea nitrogen (BUN) may indicate acute kidney injury.
  • C-Reactive Protein (CRP) / Erythrocyte Sedimentation Rate (ESR): Elevated inflammatory markers.
  • Electrolytes: May show hyponatremia.
  • Cerebrospinal Fluid (CSF) Analysis (after ruling out elevated ICP): Crucial for diagnosing encephalitis.
    • Appearance: Usually clear, sometimes mildly turbid.
    • White Blood Cell (WBC) count: Typically lymphocytic pleocytosis (50-500 cells/µL), sometimes mixed cellularity in early stages.
    • Protein: Mild to moderate elevation (50-150 mg/dL).
    • Glucose: Usually normal.
    • Gram stain/culture: Negative for bacteria.
    • India ink stain: Negative for cryptococcus.
• Confirmatory:
  • Serology for Orientia tsutsugamushi:
    • Indirect Immunofluorescence Assay (IFA): Gold standard. Detection of IgM (acute infection) and IgG (recent or past infection) antibodies. A four-fold rise in antibody titer between acute and convalescent sera (2-4 weeks apart) is diagnostic. Single titers of IgM ≥1:400 or IgG ≥1:400 in endemic areas with compatible illness are often considered diagnostic.
    • Enzyme-Linked Immunosorbent Assay (ELISA): Widely used for IgM and IgG detection, good sensitivity and specificity, easier to perform.
  • Polymerase Chain Reaction (PCR): Can detect Orientia DNA in blood, eschar biopsy, or CSF. High specificity, variable sensitivity. PCR of eschar is often more sensitive than blood. CSF PCR can confirm CNS involvement but sensitivity can be low.
• Monitoring:
  • Repeat CBC, LFTs, RFTs to monitor for resolution of organ dysfunction and drug toxicity.
  • Neurological assessments to track improvement or progression of symptoms.
  • Repeat CSF analysis rarely needed unless clinical worsening or concerns for alternative diagnoses.

Imaging

• Recommended:
  • Brain Magnetic Resonance Imaging (MRI) with and without contrast: The preferred imaging modality for encephalitis.
    • Findings: May show T2/FLAIR hyperintensities in cerebral cortex, subcortical white matter, brainstem, or cerebellum. These represent edema, inflammation, or demyelination. Patchy or diffuse leptomeningeal enhancement may be seen in meningoencephalitis. Microhemorrhages are possible. Normal MRI does not rule out encephalitis.
  • Computed Tomography (CT) Scan of the Head: Usually performed emergently to rule out other causes of altered mental status (e.g., hemorrhage, mass lesions, hydrocephalus) before lumbar puncture. Less sensitive than MRI for detecting subtle inflammatory changes of encephalitis.
• Advanced:
  • Magnetic Resonance Angiography (MRA) / Venography (MRV): May be considered if there is suspicion for vasculitis, stroke, or cerebral venous thrombosis, which can rarely complicate severe scrub typhus.
  • Electroencephalography (EEG): May show generalized slowing in diffuse encephalopathy or focal abnormalities (e.g., epileptiform discharges) in patients with seizures or focal neurological signs. Useful for detecting non-convulsive status epilepticus.

Management

Acute Management

• Immediate (First-hour interventions):
  • Airway, Breathing, Circulation (ABC) assessment and stabilization: Ensure patent airway, adequate ventilation (supplemental oxygen, intubation if necessary), and hemodynamic stability (IV fluids, vasopressors if hypotensive).
  • Empiric broad-spectrum antibiotics: If bacterial meningitis/encephalitis is suspected in the differential, start empiric antibiotics immediately (e.g., ceftriaxone, vancomycin, acyclovir for herpes simplex encephalitis) while awaiting diagnostic workup.
  • Seizure management: If present, administer benzodiazepines (e.g., lorazepam 0.1 mg/kg IV up to 4 mg, repeated once) followed by an anti-epileptic drug (e.g., levetiracetam, fosphenytoin).
  • Blood glucose check: Rule out hypoglycemia as a cause of altered mental status.
• Stabilization (Early management priorities):
  • Specific antimicrobial therapy: Initiate doxycycline immediately if scrub typhus is suspected, as delay in treatment increases morbidity and mortality.
  • Supportive care:
    • Fluid and electrolyte management.
    • Nutritional support (enteral or parenteral if prolonged NPO).
    • Fever control (antipyretics, cooling blankets).
    • Pressure ulcer prevention, deep vein thrombosis (DVT) prophylaxis.
  • Management of increased ICP: If signs of herniation or significant cerebral edema:
    • Head elevation (30 degrees).
    • Maintain normocapnia (PaCO2 35-40 mmHg).
    • Osmotic agents (e.g., mannitol 0.25-1 g/kg IV over 20-30 min, or hypertonic saline 3% 5-10 mL/kg IV bolus).
    • Consider corticosteroids (e.g., dexamethasone) in severe cases with significant cerebral edema, though evidence for routine use in scrub typhus encephalitis is limited and controversial.
• Emergency (Crisis management):
  • Respiratory failure: Mechanical ventilation.
  • Shock: Vasopressors, fluid resuscitation, treat underlying cause.
  • Refractory seizures/status epilepticus: Continuous EEG monitoring, escalation of anti-epileptic drugs, continuous infusions (e.g., propofol, midazolam).
  • Cardiac arrhythmias/myocarditis: Cardiopulmonary support, antiarrhythmics.
  • Renal failure: Dialysis if indicated.

Chronic Management

• Pharmacological:
  • Doxycycline: The drug of choice for Orientia tsutsugamushi.
    • Adults: 100 mg orally or IV every 12 hours for 7-14 days, or at least 3 days after defervescence.
    • Children (≥8 years): 2.2 mg/kg orally or IV twice daily (max 100 mg/dose) for 7-14 days. Though historically avoided in children <8 due to dental staining, the CDC and AAP now recommend doxycycline for severe rickettsial diseases in all ages due to superior efficacy and low risk of tooth staining with short courses.
    • Pregnancy: Doxycycline is generally avoided. Azithromycin is the preferred alternative.
  • Azithromycin: Alternative, especially for pregnant women or children where doxycycline is strictly contraindicated (though less favored now for young children in severe cases).
    • Adults: 500 mg orally once daily for 5 days.
    • Children: 10 mg/kg orally once daily for 5 days (max 500 mg/dose).
  • Chloramphenicol: Historically used, but less preferred due to potential for bone marrow toxicity (aplastic anemia).
    • Adults: 50 mg/kg/day orally or IV in 4 divided doses for 7-14 days.
  • Corticosteroids: Dexamethasone may be considered in severe cases with significant cerebral edema and signs of high ICP, typically in conjunction with specific antibiotics. Evidence is not strong for routine use, and some studies suggest worse outcomes if used alone.
• Non-pharmacological:
  • Rehabilitation: Physical, occupational, and speech therapy for patients with persistent neurological deficits (e.g., weakness, ataxia, cognitive impairment).
  • Nutritional support: Adequate caloric and protein intake to aid recovery.
  • Psychological support: Counseling for patients and families coping with severe illness and potential long-term sequelae.
• Monitoring:
  • Clinical status: Daily neurological exams, vital signs, input/output, mental status.
  • Laboratory: Monitor CBC, LFTs, RFTs for resolution and potential drug toxicity.
  • Rehabilitation progress: Regular assessments by therapists.
  • Neurological follow-up: Long-term follow-up with a neurologist for persistent deficits or seizure disorders.

Treatment Algorithms

• First-Line:
  1. High index of suspicion for Scrub Typhus Encephalitis: Based on epidemiology, clinical presentation (fever, altered mental status, eschar, rash).
  2. Empiric Doxycycline: Initiate immediately (adults: 100 mg BID; children: 2.2 mg/kg BID, max 100 mg/dose).
  3. Supportive Care: ABCs, fluid/electrolyte balance, seizure management, ICP management as needed.
  4. Diagnostic Workup: CSF analysis, brain imaging (MRI), specific Orientia serology and PCR.
  5. Continue Doxycycline: For 7-14 days or until 3 days after defervescence and clinical improvement.
• Second-Line:
  • Azithromycin: If doxycycline is contraindicated (e.g., pregnancy, severe allergic reaction).
  • Chloramphenicol: If doxycycline and azithromycin are not available or contraindicated.
• Refractory Cases:
  • If no clinical improvement after 48-72 hours of appropriate antibiotic therapy, consider:
    • Re-evaluation of diagnosis: Are there co-infections or alternative diagnoses (e.g., other viral encephalitides, autoimmune encephalitis, bacterial meningitis)?
    • Antibiotic resistance: Although rare, Orientia resistance to doxycycline has been reported in some regions. Consider alternative agents if resistance is suspected (e.g., azithromycin or chloramphenicol, guided by local epidemiology).
    • Complications: Search for complications like hydrocephalus, brain abscess (rare), or ongoing systemic inflammation.
    • Adjunctive therapies: Consider corticosteroids for severe cerebral edema if not already used, with careful risk-benefit assessment.

Complications

• Common:
  • Persistent headache.
  • Cognitive impairment (memory deficits, concentration issues).
  • Fatigue.
  • Psychiatric symptoms (depression, anxiety).
• Serious:
  • Seizures: Including status epilepticus.
  • Permanent neurological deficits: Hemiparesis, ataxia, cranial nerve palsies.
  • Hydrocephalus.
  • Cerebral edema and brain herniation.
  • Multi-organ dysfunction syndrome (MODS): ARDS, myocarditis, acute kidney injury, disseminated intravascular coagulation (DIC), gastrointestinal bleeding, rhabdomyolysis.
  • Death: High mortality rate (up to 30-50% in untreated severe cases, 1-10% with treatment).
• Long-term:
  • Post-encephalitic epilepsy.
  • Chronic cognitive impairment and neurobehavioral changes.
  • Persistent motor deficits.
  • Chronic fatigue syndrome-like symptoms.
  • Impact on quality of life and functional independence.

Prognosis

• Factors:
  • Timeliness of treatment: Early initiation of effective antibiotics is the single most important factor.
  • Severity of illness at presentation: Patients presenting with profound altered mental status, focal neurological deficits, or multi-organ failure have a worse prognosis.
  • Age: Extremes of age (very young, very old) may have worse outcomes.
  • Comorbidities: Underlying chronic diseases can worsen prognosis.
  • Strain virulence: Geographical variations in Orientia strain virulence may affect outcomes.
• Survival:
  • Untreated scrub typhus has a case fatality rate ranging from 6% to 30%, and can be as high as 50% in severe cases with neurological involvement.
  • With prompt and appropriate treatment, mortality rates for severe scrub typhus, including encephalitis, significantly decrease to 1-10%.
• Quality of Life:
  • Many survivors of severe scrub encephalitis make a full recovery.
  • However, a significant proportion (10-30%) may experience long-term neurological or psychological sequelae, impacting their quality of life, functional independence, and ability to return to work or school. These can include chronic fatigue, headache, memory problems, and mood disorders.

Prevention

• Primary: Preventing initial occurrence of scrub typhus.
  • Avoidance of mite-infested areas: Limit exposure to scrub brush, tall grasses, and rural vegetated areas, especially during peak seasons.
  • Protective clothing: Wear long sleeves, long pants tucked into socks or boots when outdoors in endemic areas.
  • Insect repellents: Apply repellents containing DEET (N,N-diethyl-m-toluamide) to exposed skin, and permethrin-treated clothing or gear. Follow product instructions carefully.
  • Shower after outdoor activities: To wash off any attached chiggers.
  • Vector control: Clearing vegetation around homes and campsites.
  • Vaccine development: Currently, no effective human vaccine is commercially available. Research is ongoing.
• Secondary: Early detection and intervention to prevent severe disease.
  • High index of suspicion: Clinicians in endemic areas or those evaluating travelers from these regions should consider scrub typhus in any patient presenting with fever and an unexplained rash or neurological symptoms.
  • Early diagnosis and treatment: Prompt recognition and initiation of appropriate antibiotics (doxycycline) is critical to prevent progression to severe complications like encephalitis.
• Tertiary: Preventing complications and managing long-term sequelae.
  • Rehabilitation: Early and comprehensive rehabilitation for patients with persistent neurological deficits.
  • Long-term follow-up: Neurological and psychological follow-up to address chronic issues.

Special Populations

• Pediatric:
  • Doxycycline use: Historically avoided in children <8 years due to concern for dental staining. However, for severe rickettsial diseases (including scrub typhus), the benefit of doxycycline outweighs the theoretical risk of tooth discoloration, and short courses are generally safe. The CDC and AAP recommend doxycycline as first-line for severe rickettsial infections in all ages.
  • Azithromycin: An alternative if doxycycline is not tolerated or in mild cases, but less effective for severe disease.
  • Diagnosis: Clinical presentation can be non-specific, making diagnosis challenging.
• Geriatric:
  • May present with atypical or subtle symptoms, leading to delayed diagnosis.
  • Increased risk of severe disease and complications due to comorbidities.
  • Higher risk of adverse drug reactions. Careful monitoring of renal and hepatic function during treatment is essential.
• Pregnancy:
  • Doxycycline: Contraindicated due to risk of fetal tooth discoloration and impaired bone development.
  • Azithromycin: Preferred treatment during pregnancy.
  • Chloramphenicol: Can be used as an alternative, but avoid near term due to risk of "gray baby syndrome."
  • Scrub typhus can lead to adverse pregnancy outcomes, including miscarriage, premature birth, and stillbirth. Early treatment is crucial.
• Comorbidities:
  • Immunocompromised patients: May have more severe or atypical presentations. Higher risk of complications.
  • Chronic kidney disease/liver disease: Doxycycline dose adjustment is usually not necessary in renal failure but careful monitoring is warranted. Monitor for drug-induced hepatotoxicity with doxycycline.
  • Diabetes mellitus: Patients may be more prone to infections and complications; glycemic control is important.

Clinical Pearls

• Diagnostic:
  • "Think Scrub": In any patient with acute fever, headache, altered mental status, or multi-organ involvement from an endemic area, always consider scrub typhus, especially if an eschar or rash is present.
  • The Eschar: A meticulous search for the eschar (often painless and overlooked, commonly in skin folds or areas of friction) is critical and often diagnostic.
  • CSF Findings: Lymphocytic pleocytosis with elevated protein and normal glucose is characteristic of viral encephalitis, but also seen in scrub encephalitis. CSF PCR for Orientia can be supportive but may be negative.
  • Empiric Treatment: Do not delay empiric doxycycline while awaiting confirmatory test results for scrub typhus, especially in severe cases.
• Treatment:
  • Doxycycline is King: It is the most effective treatment for scrub typhus, regardless of age, in severe cases.
  • Duration: Treatment should continue for at least 7-14 days or until the patient is afebrile for at least 3 days and clinically improving to prevent relapse.
  • Supportive Care: Aggressive supportive care is as important as specific antimicrobial therapy in severe encephalitis.
• Pitfalls:
  • Missed Diagnosis: Failure to consider scrub typhus due to lack of a classic eschar, atypical presentation, or unfamiliarity with the disease in non-endemic areas (e.g., in travelers).
  • Delayed Treatment: Significant increases in morbidity and mortality are associated with delayed initiation of effective antibiotics.
  • Inappropriate Antibiotics: Using beta-lactams or aminoglycosides, which are ineffective against Orientia, can be detrimental.
  • Over-reliance on negative PCR: A negative Orientia PCR, especially on a single blood sample, does not rule out scrub typhus, particularly with high clinical suspicion. Serology (IFA, ELISA) with acute and convalescent titers remains the gold standard.

Recent Updates

• Guidelines: Current guidelines from infectious disease societies (e.g., IDSA, CDC) continue to emphasize doxycycline as the first-line treatment for rickettsial infections, including scrub typhus, for all age groups, given the high mortality of untreated severe disease and the low risk of tooth staining with short courses.
• Evidence:
  • Ongoing research aims to improve rapid diagnostic tests for Orientia tsutsugamushi, including point-of-care PCR and antigen detection assays, to facilitate earlier diagnosis and treatment.
  • Studies continue to explore the epidemiology and clinical spectrum of scrub typhus in new or emerging endemic areas.
  • Vaccine development remains a priority, though no commercially available human vaccine is imminent.
• Controversies:
  • Corticosteroid use: The role of corticosteroids in severe scrub encephalitis with cerebral edema remains a subject of debate. While some clinicians use them in selected severe cases, robust evidence from controlled trials is lacking, and some retrospective data suggest potential for harm if used without concomitant effective antibiotics or in less severe cases.
  • Doxycycline resistance: Reports of doxycycline-resistant Orientia strains from specific regions (e.g., Thailand) highlight the importance of monitoring clinical response and considering alternative agents like azithromycin or chloramphenicol in non-responders, guided by local resistance patterns.

Key References

• Guidelines:
  • Centers for Disease Control and Prevention (CDC). Information for Healthcare Providers: Rickettsial Disease. (Regularly updated recommendations for treatment and diagnosis).
  • Infectious Diseases Society of America (IDSA). Practice Guidelines for the Diagnosis and Management of Rickettsial Diseases (While not specific to scrub typhus, often includes relevant sections).
  • World Health Organization (WHO). Guidance for clinical management of scrub typhus (Provides regional guidance).
• Studies:
  • Watt G, et al. Scrub typhus. N Engl J Med. 2000;342(15):1052-3. (Classic review on scrub typhus).
  • Peter J, et al. Clinical and laboratory features of scrub typhus at a tertiary hospital in India. Asian Pacific J Trop Med. 2018;11(1):66-70. (Example of regional clinical studies).
  • Varghese GM, et al. Doxycycline for severe scrub typhus in children. Pediatr Infect Dis J. 2013;32(1):44-6. (Supporting evidence for doxycycline use in children).
  • Paris DH, et al. A review of doxycycline in the treatment of scrub typhus. Trans R Soc Trop Med Hyg. 2011;105(3):141-8. (Comprehensive review on doxycycline).
• Reviews:
  • Lim C, et al. Neurological manifestations of scrub typhus. J Clin Neurosci. 2021;90:29-37.
  • Kim DM, et al. Clinical and laboratory findings of scrub typhus: a comparison of patients with and without central nervous system involvement. Am J Trop Med Hyg. 2006;75(6):1120-4.
  • Rani P, et al. Neurological manifestations of scrub typhus: a systematic review. J Neurol Sci. 2016;366:201-8.

---

Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must use their independent medical judgment in all patient care decisions. The information provided is based on current medical knowledge and guidelines but may not encompass all possible scenarios or individual patient variations. Always consult with relevant specialists and consider individual patient factors.